Gaudium IVF and Women Health Limited has informed the Exchange regarding 'Intimation under Regulation 8(2) of the Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015'.
GAUDIUMIVF · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gaudium IVF and Women Health Limited has submitted its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI) to BSE and NSE, as required under Regulation 8(2) of SEBI's Prohibition of Insider Trading Regulations, 2015. The code, originally approved by the Board of Directors on November 4, 2024, outlines how the company will handle and disclose price-sensitive information, identifies the Chief Investor Relations Officer for dissemination duties, and includes an Annexure A policy on legitimate purposes for sharing UPSI. The code is now hosted on the company's investor website. Naveen Kumar, Company Secretary and Compliance Officer (Membership No. A69788), signed the filing dated February 28, 2026.
This is a routine regulatory compliance filing with no direct impact on the company's financials, operations, or stock price. It reinforces the company's insider trading compliance framework, which may indirectly support investor confidence in corporate governance.